SCHEMBL25245236

SCHEMBL25245236

Cc1cc(Br)ccc1CNC(=O)c1cc(C(C)(C)C)on1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 2/20 0.51
▸ ALDH1A1 P00352 4/20 0.49
▸ MAPK1 P28482 2/20 0.44
▸ EPHX2 P34913 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ SMN1; SMN2 Q16637 5/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ NPC1 O15118 4/20 0.41
▸ RAB9A P51151 4/20 0.41
▸ MAPK14 Q16539 1/20 0.40
▸ SCD O00767 1/20 0.40
▸ SCD5 Q86SK9 1/20 0.40
▸ P2RX7 Q99572 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ TSHR P16473 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25249865 0.79 BTK (0.47) BTKALDH1A1MAPK1EPHX2MAPT
SCHEMBL17645703 0.79 BTK (0.46) BTKALDH1A1EPHX2MAPTKDM4E
SCHEMBL17645664 0.78 BTK (0.51) BTKALDH1A1MAPK1EPHX2MAPT
SCHEMBL29124706 0.77 BTK (0.51) BTKALDH1A1MAPK1EPHX2HTT
SCHEMBL17645926 0.76 EPHX2 (0.74) BTKEPHX2SMN1; SMN2CYP1A2CYP2C19
SCHEMBL23605779 0.74 BTK (0.54) BTKALDH1A1EPHX2MAPTP2RX7
SCHEMBL29418492 0.74 BTK (0.54) BTKALDH1A1EPHX2MAPTP2RX7
SCHEMBL22659381 0.74 BTK (0.52) BTKMAPK14
SCHEMBL29533029 0.74 BTK (0.52) BTKMAPK14
SCHEMBL17663699 0.73 ALDH1A1 (0.54) ALDH1A1MAPK1HTTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327380-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2024-10-03 — — US disclosed
CN-116917279-A BTK inhibitors 渤健马萨诸塞州股份有限公司 2023-10-20 — — CN disclosed
EP-4192587-A1 BTK INHIBITORS Biogen MA Inc. (US) 2023-06-14 — — EP disclosed
WO-2022032019-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2022-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327380-A1 BTK INHIBITORS BTK, SYK, LYN BTK 1/4885ALDH1A1 4508/4885MAPK1 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback